

5 May 2023

Drugs Used to Treat Asthma

Could you please answer the questions below?

1. How many patients have been treated (for any condition) in the last 4 months with:

Adult Respiratory Team

- Benralizumab 98
- Dupilumab 39
- Omalizumab 21
- Reslizumab <5
- Mepolizumab 235
- Tezepelumab 0

Paediatric Respiratory Team

- Benralizumab 0
- Dupilumab <5
- Omalizumab 0
- Reslizumab 0
- Mepolizumab <5
- Tezepelumab 0

Immunology

- Benralizumab 0
- Dupilumab 8
- Omalizumab 140
- Reslizumab 0
- Mepolizumab 0
- Tezepelumab 0

2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age groups:

Adult Respiratory Team

- Age 6 – 11 0
- Age 12 – 17 <5
- Age 18 and above 395

5 May 2023

Paediatric Respiratory Team

- **Age 6 – 11** <5 + (<5 patients 5 years old)
- **Age 12 – 17** <5

Immunology

Age 6 – 11	<5
Age 12 – 17	5
Age 18 and above	141

3. How many patients have been treated in the last 4 months by the Respiratory Medicines Department ONLY with:

Adult Respiratory Team

- **Dupilumab** 39
- **Omalizumab** 21

Paediatric Respiratory Team

- **Dupilumab** <5
- **Omalizumab** 0

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.